ClinicalTrials.gg
Sign In
CompletedNCT01248871Updated Apr 18, 2024

"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail

An interventional study of procedure:sevoflurane-remifentanil/sufentanil and volatile agent only during reperfusion in Kidney Donation/Transplantation, sponsored by University Medical Center Groningen. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To compare the renal protective properties of two currently used anaesthetic techniques - a sevoflurane-remifentanil/sufentanil combination with a propofol-remifentanil/sufentanil combination for anaesthesia in patients undergoing living donor kidney donation/transplantation.

02

Conditions studied

  • Kidney Donation/Transplantation

Keywords

  • renal
  • transplantation
  • Volatile
  • anesthetic
03

In context

Lead sponsor

University Medical Center Groningen is the lead sponsor of 625 studies on the registry; 174 are open to participants now.

Browse University Medical Center Groningen studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients: Age > 18 years

Exclusion criteria

Exclusion Criteria:

  • patient refusal
  • BMI\< 17, >35
  • neurological disorder
  • recent use of psycho-active medication, including alcohol.
  • Donor-recipient couples from the ABO-incompatible program
  • Altruistic donor
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    SEVO

    sevoflurane-remifentanil/sufentanil combination

    Drug: procedure:sevoflurane-remifentanil/sufentanil

  • Active comparator
    SERE

    volatile agent only during reperfusion

    Drug: volatile agent only during reperfusion

  • Active comparator
    propofol

    propofol-remifentanil/sufentanil

    Drug: propofol-remifentanil/sufentanil

Interventions

  • Drugprocedure:sevoflurane-remifentanil/sufentanil

    Active Comparator

  • Drugvolatile agent only during reperfusion

    Active Comparator

  • Drugpropofol-remifentanil/sufentanil

    Active Comparator

06

What researchers measure

Primary outcomes

  1. To compare the renal protective properties of two currently used anaesthetic techniques

    Time frame: participants will be followed for the duration of hospital stay

07

Study locations

1 site
  • University Medical Center Groningen
    Groningen, 9713 EZ, Netherlands
08

References and documents

Publications

  • Nieuwenhuijs-Moeke GJ, Nieuwenhuijs VB, Seelen MAJ, Berger SP, van den Heuvel MC, Burgerhof JGM, Ottens PJ, Ploeg RJ, Leuvenink HGD, Struys MMRF. Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial. Br J Anaesth. 2017 May 1;118(5):720-732. doi: 10.1093/bja/aex057. PubMed 28510740 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01248871
Lead sponsor
University Medical Center Groningen
Responsible party
Sponsor
First posted
Nov 25, 2010
Start date
Sep 2010
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Apr 18, 2024

Study contacts

M.M.R.F Struys, Prof.dr.
principal investigator · University Medical Center Groningen
R,J. Ploeg, Prof.dr
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Medical Center Groningen →

Start the discussion